Vis enkel innførsel

dc.contributor.authorCalvo-Lerma, Joaquim
dc.contributor.authorMartinez-Jimenez, Celia P
dc.contributor.authorLazaro-Ramos, Juan-Pablo
dc.contributor.authorAndrés, Ana
dc.contributor.authorCrespo-Escobar, Paula
dc.contributor.authorStav, Erlend
dc.contributor.authorSchauber, Cornelia
dc.contributor.authorPannese, Lucia
dc.contributor.authorHulst, Jessie M
dc.contributor.authorSuarez, Lucrecia
dc.contributor.authorColombo, Carla
dc.contributor.authorBarreto, Celeste
dc.contributor.authorDe Boeck, Kris
dc.contributor.authorRibes-Koninckx, Carmen
dc.date.accessioned2018-02-01T12:59:22Z
dc.date.available2018-02-01T12:59:22Z
dc.date.created2018-01-31T11:20:58Z
dc.date.issued2017
dc.identifier.citationBMJ Open, 2017, 7 (3), 10 pagesnb_NO
dc.identifier.issn2044-6055
dc.identifier.urihttp://hdl.handle.net/11250/2481228
dc.description.abstractIntroduction: For the optimal management of children with cystic fibrosis, there are currently no efficient tools for the precise adjustment of pancreatic enzyme replacement therapy, either for advice on appropriate dietary intake or for achieving an optimal nutrition status. Therefore, we aim to develop a mobile application that ensures a successful nutritional therapy in children with cystic fibrosis. Methods and analysis: A multidisciplinary team of 12 partners coordinate their efforts in 9 work packages that cover the entire so-called ‘from laboratory to market’ approach by means of an original and innovative co-design process. A cohort of 200 patients with cystic fibrosis aged 1–17 years are enrolled. We will develop an innovative, clinically tested mobile health application for patients and health professionals involved in cystic fibrosis management. The mobile application integrates the research knowledge and innovative tools for maximising self-management with the aim of leading to a better nutritional status, quality of life and disease prognosis. Bringing together different and complementary areas of knowledge is fundamental for tackling complex challenges in disease treatment, such as optimal nutrition and pancreatic enzyme replacement therapy in cystic fibrosis. Patients are expected to benefit the most from the outcomes of this innovative project. Ethics and dissemination: The project is approved by the Ethics Committee of the coordinating organisation, Hospital Universitari La Fe (Ref: 2014/ 0484). Scientific findings will be disseminated via journals and conferences addressed to clinicians, food scientists, information and communications technology experts and patients. The specific dissemination working group within the project will address the wide audience communication through the website (http://www. mycyfapp.eu), the social networks and the newsletter.nb_NO
dc.language.isoengnb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleInnovative approach for self-management and social welfare of children with cystic fibrosis in Europe: Development, validation and implementation of an mHealth tool (MyCyFAPP)nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber10nb_NO
dc.source.volume7nb_NO
dc.source.journalBMJ Opennb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1136/bmjopen-2016-014931
dc.identifier.cristin1558070
cristin.unitcode7401,90,13,0
cristin.unitnameSystemutvikling og sikkerhet
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal